215 related articles for article (PubMed ID: 18537767)
1. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin in health and disease with a focus on affective disorders.
Zelena D
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):286-303. PubMed ID: 22954353
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin.
Goncharova ND; Chigarova OA; Oganyan TE
Bull Exp Biol Med; 2018 Nov; 166(1):86-91. PubMed ID: 30450521
[TBL] [Abstract][Full Text] [Related]
5. Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice.
Thoeringer CK; Erhardt A; Sillaber I; Mueller MB; Ohl F; Holsboer F; Keck ME
J Psychopharmacol; 2010 May; 24(5):733-43. PubMed ID: 19346277
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
[TBL] [Abstract][Full Text] [Related]
7. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
Ströhle A
Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression.
Scott LV; Dinan TG
Life Sci; 1998; 62(22):1985-98. PubMed ID: 9627097
[TBL] [Abstract][Full Text] [Related]
9. Vasopressin V1B Receptor Antagonists as Potential Antidepressants.
Chaki S
Int J Neuropsychopharmacol; 2021 Jul; 24(6):450-463. PubMed ID: 33733667
[TBL] [Abstract][Full Text] [Related]
10. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression.
Schüle C; Baghai TC; Eser D; Rupprecht R
Expert Rev Neurother; 2009 Jul; 9(7):1005-19. PubMed ID: 19589050
[TBL] [Abstract][Full Text] [Related]
11. ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease.
Esmaeili MH; Bahari B; Salari AA
Brain Res Bull; 2018 Mar; 137():265-276. PubMed ID: 29307659
[TBL] [Abstract][Full Text] [Related]
12. Involvement of vasopressin in affective disorders.
Surget A; Belzung C
Eur J Pharmacol; 2008 Apr; 583(2-3):340-9. PubMed ID: 18255056
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin as a target for antidepressant development: an assessment of the available evidence.
Scott LV; Dinan TG
J Affect Disord; 2002 Nov; 72(2):113-24. PubMed ID: 12200202
[TBL] [Abstract][Full Text] [Related]
14. Exposure to Chronic Mild Stress Differentially Alters Corticotropin-Releasing Hormone and Arginine Vasopressin mRNA Expression in the Stress-Responsive Neurocircuitry of Male and Female Rats Prenatally Exposed to Alcohol.
Lan N; Hellemans KG; Ellis L; Weinberg J
Alcohol Clin Exp Res; 2015 Dec; 39(12):2414-21. PubMed ID: 26578428
[TBL] [Abstract][Full Text] [Related]
15. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
Valdez GR
CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
17. Agarwood Essential Oil Ameliorates Restrain Stress-Induced Anxiety and Depression by Inhibiting HPA Axis Hyperactivity.
Wang S; Wang C; Yu Z; Wu C; Peng D; Liu X; Liu Y; Yang Y; Guo P; Wei J
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400578
[TBL] [Abstract][Full Text] [Related]
18. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
Griebel G; Stemmelin J; Gal CS; Soubrié P
Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
[TBL] [Abstract][Full Text] [Related]
19. Innovative approaches for the treatment of depression: targeting the HPA axis.
Thomson F; Craighead M
Neurochem Res; 2008 Apr; 33(4):691-707. PubMed ID: 17960478
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the vasopressin system for the treatment of CNS diseases.
Ryckmans T
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
